Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage
msm
The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte
1 other identifier
interventional
100
1 country
1
Brief Summary
To delineate the effect of MSM on osteoarthritis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Sep 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2012
CompletedFirst Submitted
Initial submission to the registry
March 13, 2013
CompletedFirst Posted
Study publicly available on registry
April 22, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2013
CompletedApril 22, 2013
April 1, 2013
1 year
March 13, 2013
April 17, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of participants with improved Mobility
Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC)
26 weeks
Secondary Outcomes (1)
Pain Scores on the Visual Analog Scale
26 weeks
Study Arms (2)
MSM group
EXPERIMENTALIntervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
Placebo Group
PLACEBO COMPARATORPlacebo 3 gr twice a day for 26 weeks (6 gr/day total)
Interventions
Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
Eligibility Criteria
You may qualify if:
- Knee and hip OA
- men and women \>45 years of age
You may not qualify if:
- any other type of arthritis
- chronic pain syndrome
- arthroscopic surgery in the past 8 months
- intra-articular corticosteroidsin the past 8 months
- hyaluronic acid injections in the past 8 months
- narcotic pain killers use
- renal or hepatic disease
- body mass index (BMI) \>45 kg/m2
- cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
G. Papanikolaou Hospital
Thessaloniki, Thessaloniki, 57010, Greece
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas Pagonis, MD, PhD
Aristotle's University of Thessaloniki
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Orthopaedic Surgeon
Study Record Dates
First Submitted
March 13, 2013
First Posted
April 22, 2013
Study Start
September 1, 2012
Primary Completion
September 1, 2013
Study Completion
October 1, 2013
Last Updated
April 22, 2013
Record last verified: 2013-04